What lessons can be learned from the launch of generic clopidogrel?
Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 2
Abstract
Introduction and study objectives: Resource pressures will continue to grow. Consequently, health authorities and health insurance agencies need to take full advantage of the availability of generics in order to continue funding comprehensive health care particularly in Europe. Generic clopidogrel provides such an opportunity in view of appreciable worldwide sales of the originator. However, early formulations contained different salts and only limited indications. Consequently, there is a need to assess responses by the authorities to the early availability of generic clopidogrel including potential reasons preventing them from taking full advantage of the situation. In addition, it is necessary to determine the extent of initial price reductions obtained in practice to guide future activities. Methods: Feedback from health authorities and health insurance personnel involved with the reforms surrounding generic clopidogrel was principally used to assess authority responses as there is limited information in the public domain. Abu Dhabi has been included as a representative of the Middle East since it has introduced compulsory international non-proprietary name (INN) prescribing except for limited situations. Generic clopidogrel is not one of these – providing direction to other health authorities alongside, e.g. Lithuania. Australia has also been included in view of the high court ruling in favour of generic clopidogrel. Results: Authorities from across Australia, Europe and the Middle East typically adopted a pragmatic approach to the availability of generic clopidogrel to enhance its prescribing and dispensing once approved by regulatory agencies such as EMA. This included guidance to enhance its utilisation such as academic publications, co-payment incentives and compulsory INN prescribing. However, this was not always possible with challenges to the availability of generics in some countries. Again, there was appreciable variation in the initial price reductions for generic clopidogrel versus the originator. Conclusion: Authorities can take full advantage of the early availability of generics despite different formulations and indications. Pharmaceutical companies need to accept this in order to help fund new premium price products as resource pressures grow.
Authors and Affiliations
Christoph Baumgärtel, Brian Godman, Rickard E Malmstrom, Morten Andersen, Mohammed Abuelkhair, Shajahan Abdu, Marion Bennie, Iain Bishop, Thomas Burkhardt, Sahar Fahmy, Jurij Furst, Kristina Garuoliene, Harald Herholz, Marija Kalaba, Hanna Koskinen, Ott Laius, Julie Lonsdale, Kamila Malinowska, Anne M Ringerud, Ulrich Schwabe, Catherine Sermet, Peter Skiold, Ines Teixeira, Menno van Woerkom, Agnes Vitry, Luka Vončina, Corrine Zara, Lars L Gustafsson
Keywords
Related Articles
- EP ID EP355152
- DOI 10.5639/gabij.2012.0102.016
- Views 110
- Downloads 0
ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entities
The International Conference on Harmonisation (ICH) has endorsed a new guideline concerning the development and manufacture of chemical and biotechnological/biological drug substances. The guideline harmonises the scient...
Equal protection under the law: Children and the Best Pharmaceuticals for Children Act
Four changes to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act will markedly improve these programmes: expanded attention paid to neonatal studies, support for the off -patent programme,...
Tighter EU rules on pharmacovigilance for biologicals
The new EU pharmacovigilance legislation which comes into force in July 2012 will include a tightening of requirements relating to product information and identification, as well as the regulations surrounding biosimilar...
Editor’s introduction to the wide range of topics in the initial issue of the second volume of GaBI Journal
We start off the second year of GaBI Journal with articles covering a wide range of issues.
Biologicals and biosimilars: a review of the science and its implications
Biopharmaceuticals are medicines whose active drug substance is made by living cells. Copies of these drugs, called biosimilars, are not identical to their reference drug and therefore specific regulatory requirements fo...